Testing a new biologic for moderate to severe plaque psoriasis
Treatments studied
Part of Skin clinical trials.
This study tests a biologic called vunakizumab for people with moderate to severe plaque psoriasis who are already on biologic therapy and need to switch to another one. The goal is to see if it works well and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have moderate to severe plaque psoriasis.
- You have been on biologic treatment for at least 12 weeks before screening.
- Your doctor agrees you should switch biologics as per current guidelines.
- You have not tried an IL-17A inhibitor before and failed on it, or had a bad reaction to it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called vunakizumab to see if it is safe and works well for people with moderate to severe plaque psoriasis. If you have not used biologic treatments before and meet other health requirements, you may be able to join.
This study tests a new injectable medicine for people with moderate-to-severe plaque psoriasis. It aims to see if it is safe and effective at reducing symptoms like redness and scaling.
This trial tests a new drug called Vunakizumab for people with mild to moderate lupus that affects the skin or joints. It aims to see if adding this drug to your current treatment can help control symptoms better.
This trial tests whether a combination of two drugs (vunakizumab and recaticimab) can help people who have both moderate-to-severe plaque psoriasis and high cholesterol. It aims to see if the treatment is safe and effective for both conditions.
This trial is testing the drug vunakizumab in people with inflammatory skin diseases. It aims to see how well the treatment works for different skin conditions.
This trial tests a new biologic drug called Vunakizumab for adults with spondyloarthritis (a type of arthritis affecting the spine). It aims to see if the drug can help control symptoms and inflammation.
Hear when a new Moderate to Severe Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.